219 related articles for article (PubMed ID: 2802800)
21. Clinical distribution of anticentromere antibody in Japanese patients.
Soma Y; Takehara K; Ishibashi Y
Dermatologica; 1989; 178(1):16-9. PubMed ID: 2645177
[TBL] [Abstract][Full Text] [Related]
22. The anticentromere antibody: disease specificity and clinical significance.
Powell FC; Winkelmann RK; Venencie-Lemarchand F; Spurbeck JL; Schroeter AL
Mayo Clin Proc; 1984 Oct; 59(10):700-6. PubMed ID: 6384675
[TBL] [Abstract][Full Text] [Related]
23. Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants.
McCarty GA; Rice JR; Bembe ML; Barada FA
Arthritis Rheum; 1983 Jan; 26(1):1-7. PubMed ID: 6337593
[TBL] [Abstract][Full Text] [Related]
24. [Anticentromere antibodies in rheumatoid polyarthritis with Sjögren syndrome, without the elements of the CREST syndrome].
Lorcerie B; Tavernier C; Olsson O; Strauss J; Martin F
Rev Rhum Mal Osteoartic; 1988 Mar; 55(4):291-2. PubMed ID: 3259719
[No Abstract] [Full Text] [Related]
25. [Clinical significance of anticentromere antibody assay].
Moteki S
Nihon Rinsho; 1990 Feb; 48 Suppl():580-3. PubMed ID: 2192153
[No Abstract] [Full Text] [Related]
26. The clinical significance of the anticentromere antibody.
Miller MH; Littlejohn GO; Davidson A; Jones B; Topliss DJ
Br J Rheumatol; 1987 Feb; 26(1):17-21. PubMed ID: 3493051
[TBL] [Abstract][Full Text] [Related]
27. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
28. Anticentromere antibody in localized scleroderma.
Ruffatti A; Peserico A; Glorioso S; Fiocco U; Rossi L; Gambari P; Todesco S
J Am Acad Dermatol; 1986 Oct; 15(4 Pt 1):637-42. PubMed ID: 3534010
[TBL] [Abstract][Full Text] [Related]
29. Anticentromere antibodies--clinical correlates.
Wade JP; Sack B; Schur PH
J Rheumatol; 1988 Dec; 15(12):1759-63. PubMed ID: 3265957
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of methods for detection of anticentromere antibodies and other antinuclear antibodies.
Beutner EH; Krasny SA; Chorzelski TP; Rodnan G; Jablonska S; Kumar V
J Am Acad Dermatol; 1985 Feb; 12(2 Pt 1):289-95. PubMed ID: 3882784
[TBL] [Abstract][Full Text] [Related]
31. Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population.
Catoggio LJ; Skinner RP; Maddison PJ
Rheumatol Int; 1983; 3(1):19-21. PubMed ID: 6412349
[TBL] [Abstract][Full Text] [Related]
32. Human fibroblasts, a convenient nuclear substrate for detection of anti-nuclear antibodies including anti-centromere antibodies.
Kallenberg CG; van der Meulen J; Pastoor GW; Snijder JA; Feltkamp TE; The TH
Scand J Rheumatol; 1983; 12(3):193-200. PubMed ID: 6414079
[TBL] [Abstract][Full Text] [Related]
33. Anticentromere antibodies: clinical and biological significance.
Fritzler MJ; Ayer LM
J Rheumatol; 1982; 9(4):489-90. PubMed ID: 6982333
[No Abstract] [Full Text] [Related]
34. Differential isotype recognition of two centromere associated polypeptides by immunoblotting in connective tissue disease.
McHugh NJ; James IE; Maddison PJ
Clin Exp Immunol; 1988 Jun; 72(3):457-64. PubMed ID: 3048806
[TBL] [Abstract][Full Text] [Related]
35. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.
Weiner ES; Earnshaw WC; Senécal JL; Bordwell B; Johnson P; Rothfield NF
Arthritis Rheum; 1988 Mar; 31(3):378-85. PubMed ID: 2833902
[TBL] [Abstract][Full Text] [Related]
36. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations.
Aeschlimann A; Meyer O; Bourgeois P; Haim T; Belmatoug N; Palazzo E; Kahn MF
Ann Rheum Dis; 1989 Dec; 48(12):992-7. PubMed ID: 2515813
[TBL] [Abstract][Full Text] [Related]
37. Anticentromere antibodies in rheumatologic practice are not consistently associated with scleroderma.
Tubach F; Hayem G; Elias A; Nicaise P; Haim T; Kahn MF; Meyer O
Rev Rhum Engl Ed; 1997 Jun; 64(6):362-7. PubMed ID: 9513607
[TBL] [Abstract][Full Text] [Related]
38. Clinical correlation of anticentromere antibodies.
Zuber M; Gotzen R; Filler I
Clin Rheumatol; 1994 Sep; 13(3):427-32. PubMed ID: 7835004
[TBL] [Abstract][Full Text] [Related]
39. [The titers and complement-activating abilities of anticentromere antibody in systemic sclerosis, other connective tissue diseases, and other related conditions].
Sato S; Takehara K; Ishibashi Y
Nihon Hifuka Gakkai Zasshi; 1991 Feb; 101(2):97-104. PubMed ID: 2072581
[TBL] [Abstract][Full Text] [Related]
40. Raynaud's phenomenon, anticentromere antibodies, and digital necrosis without sclerodactyly: an entity independent of scleroderma?
Sachsenberg-Studer EM; Prins C; Saurat JH; Salomon D
J Am Acad Dermatol; 2000 Oct; 43(4):631-4. PubMed ID: 11004618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
